Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

• Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primar…
• https://x.com/RichardPAConway/status/1858513994107297997/photo/1

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1

Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb

• https://x.com/synovialjoints/status/1858512713560805401/photo/1

Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx

• Shifting Trends in Initial RA Treatment Approaches | RheumNow

Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies: - spontaneous loss rate comparable to non-disease controls - no stillbirths - preterm similar to disease controls Plenty positive for CZP in pregnancy! #ACR24 ABST0805 @RheumNow https://t.co/XCRYsioxC0

• https://x.com/drdavidliew/status/1858507578621538780/photo/1

A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA). Key findings: - Among patients initially at LDA, achieving remission (CDAI ≤2.8) led to significantly better functional outcomes and reduced durable medical equipment… https://t.co/SNPKlRieur https://t.co/YIQNMf3Oap

• https://x.com/i/web/status/1858506696001474854
• https://x.com/synovialjoints/status/1858506696001474854/photo/1

Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24

Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution. Persistent higher doses earlier on might dampen ICI response. @HSpecialSurgery ICI-IA (inflamm arthritis) cohort big diff in survival based on early steroid exposure #ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw

• https://x.com/drdavidliew/status/1858483970268401794/photo/1

Rheumatic irAEs can get on the CAR-T bandwagon, too! CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience. Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to... #ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr

• https://x.com/drdavidliew/status/1858485108338291164/photo/1

Now that nipocalimab is approved for Sjogren's Disease, what about vaccination response whilst on this FcRn inhibitor (inherently lowers IgG)? Actually, not bad: takes a little longer to get there, but reassuring! (always fun to get to know a new med) #ACR24 ABST1988 @RheumNow https://t.co/IYqIGo5xVP

• https://x.com/drdavidliew/status/1858486947909636452/photo/1